Implementing AI-Assisted, Patient-Friendly Imaging Report Summaries to Enhance Oncology Care Delivery

April 28, 2026 updated by: University of Wisconsin, Madison
The implementation of the AI-assisted radiology summary tool into clinical workflows is being conducted as part of a standard-of-care quality improvement (QI) initiative at UW Health. The evaluation of this tool's impact via structured feedback from patients and providers is being undertaken as a prospective research study.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Patient groups: Mixed-method approach to evaluate patient understanding of, and anxiety about, imaging results and communication experience regarding the results before and after implementation of AI-assisted, patient-friendly imaging report summaries that accompany the imaging results.

Provider group: Quasi-experimental staircase approach to sequentially roll out the tool to three provider cohorts. All hematology/oncology and gynecology oncology attending providers will be randomized by disease group into three relatively similar-sized cohorts based on group-level scan volumes, regardless of individual provider characteristics or communication style. Subsequent cohorts will be added every two months.

Surveys will be the main method of feedback collection at baseline and after implementation of the AI-assisted, patient-friendly imaging report summaries. Interviews will be conducted in a small subset of subjects.

Primary Objective:

  • To evaluate patient comprehension of, and anxiety about, imaging results and communication experience regarding the results before and after implementation of AI-assisted, patient-friendly imaging report summaries that accompany the imaging results.

Secondary Objective(s):

  • Patient Baseline Survey Objective: To evaluate comprehension of, and anxiety about, imaging results and communication experience regarding the results before the implementation of the AI-assisted, patient-friendly imaging report summaries that accompany the imaging results.
  • Patient Summary Feedback Survey Objective: To evaluate comprehension of, and anxiety about, imaging results and communication experience regarding the results after the implementation of the AI-assisted, patient-friendly imaging report summaries that accompany the imaging results.
  • Patient Interview Objectives: To understand the imaging result communication process from the patient's perspective.
  • Provider Surveys Objective: The Baseline Survey will assess communication habits and preferences (frequency, method, timing), and perceived impact of the AI-Assisted, Patient-Friendly Imaging Report Summaries on clinical workload, and the Post-Implementation Surveys will evaluate changes in workload perception, satisfaction with the AI-Assisted, Patient-Friendly Imaging Report Summaries, the effectiveness of scan result communication with patients, and attitudes toward the use of AI-assisted material in patient care.

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • Recruiting
        • UW Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Cancer patients undergoing imaging studies as part of their routine clinical care at UW Health and providers who have access to the scan summary tool.

Description

Inclusion Criteria (Patient Participants):

  • Age 18 years or older
  • Having a current or prior cancer diagnosis (any cancer type)
  • Has active access to the UW Health MyChart patient portal.
  • Receiving care at UW Health within the Division of Hematology, Medical Oncology and Palliative Care or Department of Gynecologic Oncology.
  • Undergoing imaging studies (such as CT, MRI, or PET scans) as part of routine cancer care.
  • Willing and able to complete electronic REDCap surveys.
  • For interview participation: willing to participate in a 30-45-minute phone or video interview.

Inclusion Criteria (Provider Participants): Cancer care providers will be eligible to participate in this study if they meet all of the following criteria:

  • Faculty physician (MD or DO) practicing in the Division of Hematology, Medical Oncology and Palliative Care or Department of Gynecologic Oncology at UW Health.
  • Involved in reviewing, discussing, or sharing imaging results with patients.
  • Planned to gain access to the AI-assisted, patient-friendly imaging summary tool as part of clinical implementation.
  • Willing and able to complete electronic surveys or participate in a brief interview (~30 minutes).

Exclusion Criteria (Patients):

  • Are unable to provide informed consent due to cognitive impairment or other limitations, as determined by the clinical or study team.
  • Enrolled in an active interventional clinical trial. Patients on biospecimen, registry, or non-interventional studies are eligible.
  • For the Patient Interview group only: Patients with radiographic disease progression will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patient Participants
  • Patient Baseline Survey (pre-implementation, at least 330 participants, up to 1900)
  • Patient Interviews (10-20 participants)
  • Patient Summary Feedback Survey (post-implementation, at least 330 participants, up to 1900)
Provider Participants
  • Provider Surveys (baseline, 1 month and 3 month post-implementation, 60 participants)
  • Provider Interviews (up to 20 participants)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Patient Participants who report the information presented in their results is "Somewhat easy to understand" or "Very easy to understand" when reviewed by themselves
Time Frame: up to 15 minutes
Baseline data collected in a 10-15 minute survey from patient participants pre-implementation and in a 10-15 minute survey from patient participants post-implementation.
up to 15 minutes
Perceived impact of scan-result-related patient queries on Provider Participant workload
Time Frame: baseline, 3 months
Scored from 1 (no impact) to 5 (very frequently), higher scores indicate higher impact on workload. Data collected at baseline (pre-implementation) and 3 months (post-implementation).
baseline, 3 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Patient Participants who report that reviewing scans increases their anxiety
Time Frame: up to 15 minutes
Baseline data collected in a 10-15 minute survey from patient participants pre-implementation and in a 10-15 minute survey from patient participants post-implementation.
up to 15 minutes
Proportion of Patient Participants who report that they were "somewhat" or "very" satisfied with how scan results were shared and explained
Time Frame: up to 15 minutes
Baseline data collected in a 10-15 minute survey from patient participants pre-implementation and in a 10-15 minute survey from patient participants post-implementation.
up to 15 minutes
Proportion of Patient Participants who report that they "almost always" or "often" contact their provider to ask questions regarding their scan results prior to their follow-up visit
Time Frame: up to 15 minutes
Baseline data collected in a 10-15 minute survey from patient participants pre-implementation and in a 10-15 minute survey from patient participants post-implementation.
up to 15 minutes
Provider Participant-reported frequency of scan-result-related patient queries
Time Frame: baseline, 3 months
Scored from 1 (never) to 5 (very frequently), higher scores indicate higher frequency. Data collected at baseline (pre-implementation) and 3 months (post-implementation).
baseline, 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hamid Emamekhoo, MD, UW School of Medicine and Public Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

April 8, 2026

First Submitted That Met QC Criteria

April 8, 2026

First Posted (Actual)

April 15, 2026

Study Record Updates

Last Update Posted (Actual)

April 30, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-1716
  • UW25122 (Other Identifier: OnCore ID)
  • SMPH/DOM Hemato Med Onc (Other Identifier: UW Madison)
  • Protocol Version 4/9/26 (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oncology

Subscribe